Ophthalmology

Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake

October 24th 2023

By Skylar Jeremias

Article

Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.

Eye on Pharma: Another CRL for Alvotech; Cimerli’s Growing Market Share; BBCIC Awarded Grant

October 19th 2023

By Skylar Jeremias

Article

Alvotech received a complete response letter (CRL) for its ustekinumab biosimilar; Formycon’s Cimerli, a ranibizumab biosimilar, achieved 25% market share in the United States; and the FDA awarded a researach grant to the Biologics & Biosimilars Collective Intelligence Consortium (BBCIC).

Samsung Bioepis Presents Positive Phase 3 Data on Aflibercept Candidate

October 9th 2023

By Skylar Jeremias

Article

At EURETINA 2023, Samsung Bioepis shared positive comparative efficacy data on its aflibercept biosimilar candidate, demonstrating that the product is as safe and effective as the originator (Eylea).

Higher-Cost Therapies for ARMD Could Contribute to Heightened Medicare Costs; Biosimilars Could Help

September 24th 2023

By Justina Petrullo

Article

Drug maker payments to ophthalmologists were associated with the choice of higher-cost therapies for age-related macular degeneration (ARMD) that could increase Medicare costs, but biosimilars could help.

European Commission Approves First Aflibercept Biosimilar

September 21st 2023

By Skylar Jeremias

Article

The European Commission approved the first aflibercept biosimilar, which will be used to treat patients with age-related macular degeneration and diabetic macular edema.

Biocon Biosimilar Quarterly Sales Up 106%

August 17th 2023

By Skylar Jeremias

Article

In Biocon’s latest quarterly earnings report, the company revealed that sales for its biosimilars portfolio rose 106% compared with the same time frame the year prior.

STADA Earnings Project Record Breaking Profits for 2023

August 16th 2023

By Skylar Jeremias

Article

In STADA Arzneimittel’s first half of 2023 earnings report, the company disclosed double-digit growth, suggesting that it could see profits hit an all-time high by the end of the year.

Study: Ranibizumab Biosimilar Is the Most Cost-Effective Option for nAMD

August 15th 2023

By Justina Petrullo

Article

Ranibizumab biosimilar was found to be the most cost-effective for neovascular age-related macular degeneration (nAMD), according to a recent Japanese study.

Biosimilar Business News Recap: 3 Biosimilar Application Submissions; Roche Sues Biogen

July 26th 2023

By Skylar Jeremias

Article

Formycon and Celltrion announced the FDA submissions for their aflibercept biosimilars; the European Medicines Agency accepted a marketing authorization application for an ustekinumab biosimilar; and Roche filed suit against Biogen over a tocilizumab biosimilar.

Eye on Pharma: Omalizumab Results; Korean Insulin Launch; Quebec to Cover Byooviz

July 12th 2023

By Skylar Jeremias

Article

Kashiv Biosciences announced positive phase 1 results for its omalizumab biosimilar; Dongkook Pharmaceutical shared the launch of an insulin glargine biosimilar (Glargia); and Quebec, a province in Canada, said it’s adding a ranibizumab biosimilar (Byooviz) to its reimbursement list.